Dupilumab sustains efficacy in patients with moderate‐to‐severe type 2 asthma regardless of inhaled corticosteroids dose
Allergy · 2023-11 · 78 (11) · 2921-2932
DOI: 10.1111/all.15792 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Allergy, online erschienen am 11.07.2023. Verfasst von Ian D Pavord und 13 weiteren Autor:innen. Beteiligte Einrichtung: NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: Anti-Asthmatic Agents, Asthma. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Regeneron Pharmaceuticals Inc., Sanofi.
Abstract (Originalsprache)
Background
Dupilumab, a human monoclonal antibody, blocks the shared receptor component for interleukins‐4/13, key and central drivers of type 2 inflammation. The TRAVERSE (NCT02134028) open‐label extension study demonstrated the long‐term safety and efficacy of dupilumab in patients ≥12 years who completed a previous dupilumab asthma study. The safety profile was consistent with that observed in the parent studies. Here, we assess whether dupilumab sustains long‐term efficacy in patients regardless of inhaled corticosteroid (ICS) dose at parent study baseline (PSBL).
Methods
Patients from phase 2b (NCT01854047) or phase 3 (QUEST; NCT02414854) studies receiving high‐ or medium‐dose ICS at PSBL and enrolled in TRAVERSE were included. We analyzed unadjusted annualized severe exacerbation rates, change from PSBL in pre‐bronchodilator (BD) forced expiratory volume in 1 second (FEV 1 ), 5‐item asthma control questionnaire, and type 2 biomarkers in patients with type 2 asthma at baseline (blood eosinophils ≥150 cells/μL or fractional exhaled nitric oxide [FeNO] ≥25 ppb), and subgroups defined by baseline blood eosinophils or FeNO.
Results
Of patients with type 2 asthma ( n = 1666), 891 (53.5%) were receiving high‐dose ICS at PSBL. In this subgroup, unadjusted exacerbation rates for dupilumab versus placebo were 0.517 versus 1.883 (phase 2b) and 0.571 versus 1.300 (QUEST) over the parent study (52 weeks) and remained low throughout TRAVERSE (0.313–0.494). Improvements in pre‐BD FEV 1 were sustained throughout TRAVERSE. Similar clinical efficacy was observed among patients receiving medium‐dose ICS at PSBL and biomarker subgroups.
Conclusions
Dupilumab showed sustained efficacy for up to 3 years in patients with uncontrolled, moderate‐to‐severe type 2 asthma on high‐ or medium‐dose ICS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
- Department of Respiratory Diseases, University of Montpellier, Montpellier, France.
- Respiratory Medicine Unit, University of Ferrara, S. Anna University Hospital, Ferrara, Italy.
- Pulmonary Service, Corporació Sanitària Parc Taulí, Sabadell, Autonomous University of Barcelona, Barcelona, Spain.
- David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
- Sanofi, Cambridge, Massachusetts, USA.
ORCID-Profile: Ian D Pavord, Arnaud Bourdin, Alberto Papi, Christian Domingo, Jonathan Corren, Arman Altincatal, Amr Radwan, Nami Pandit-Abid, Juby A Jacob-Nara, David J Lederer, Megan Hardin
Förderung
- Regeneron Pharmaceuticals Inc.
- Sanofi
Zitieren
APA
Pavord, I. D., Bourdin, A., Papi, A., Domingo, C., Corren, J., Altincatal, A., Radwan, A., Pandit-Abid, N., Jacob-Nara, J. A., Deniz, Y., Rowe, P. J., Laws, E., Lederer, D. J., & Hardin, M. (2023). Dupilumab sustains efficacy in patients with moderate‐to‐severe type 2 asthma regardless of inhaled corticosteroids dose. Allergy, 78(11), 2921-2932. https://doi.org/10.1111/all.15792
Vancouver
Pavord ID, Bourdin A, Papi A, Domingo C, Corren J, Altincatal A, et al. Dupilumab sustains efficacy in patients with moderate‐to‐severe type 2 asthma regardless of inhaled corticosteroids dose. Allergy. 2023;78(11):2921-2932. doi:10.1111/all.15792
BibTeX
@article{Pavord2023,
author = {Pavord, Ian D and Bourdin, Arnaud and Papi, Alberto and Domingo, Christian and Corren, Jonathan and Altincatal, Arman and Radwan, Amr and Pandit-Abid, Nami and Jacob-Nara, Juby A and Deniz, Yamo and Rowe, Paul J and Laws, Elizabeth and Lederer, David J and Hardin, Megan},
title = {Dupilumab sustains efficacy in patients with moderate‐to‐severe type 2 asthma regardless of inhaled corticosteroids dose},
journal = {Allergy},
year = {2023},
volume = {78},
number = {11},
pages = {2921--2932},
doi = {10.1111/all.15792}
}
EUVIMED